We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Genzyme and Canadian drugmaker AnorMED have announced the completion of Genzyme's tender offer to acquire all of the outstanding shares of AnorMED for $13.50 per share, or approximately $584 million.
With an estimated 930,000 new HIV infections in Asia and the Pacific region last year, United Nations agencies have called for urgent efforts to prevent the escalating spread of the virus and reduce mortality by better integrating HIV prevention, treatment and care into maternal and newborn health services.
Aurobindo Pharma, based in India, has received marketing authorization approval from Medicines Control Council (MCC) of South Africa for generic stavudine tablets in 30- and 40-mg strengths.
Barr Pharmaceuticals announced that its Duramed Pharmaceuticals subsidiary has begun shipping the dual-label Plan B (levonorgestrel) emergency contraceptive OTC/Rx product.
Swiss drugmaker Novartis announced today that Prexige, a selective COX-2 inhibitor anti-inflammatory drug, has been cleared for approval in the European Union (EU) as a new treatment option for patients with osteoarthritis.
There has been a mixed reaction in Pakistan to a government decision to establish a national Drug Regulatory Authority (DRA) to standardize the quality of medicines and streamline their registration, UN Integrated Regional Information Networks (IRIN) reports.
An estimated 7.8 million children in Sudan will be targeted in the next round of a UN-backed polio immunization campaign, despite ongoing security concerns.
U.S. drugmakers Abbott and Kos Pharmaceuticals announced today a definitive agreement under which Abbott will acquire Kos for $78 per share in cash, for a total transaction value of $3.7 billion.
As extremely drug-resistant tuberculosis (XDR-TB) threatens to make the TB pandemic worse, the Dutch Ministry of Foreign Affairs has made a four-year investment of 18.4 million euros in the Aeras Global TB Vaccine Foundation to develop new TB vaccines.